CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 110 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $75,953 | +37.3% | 50,300 | +45.5% | 0.00% | – |
Q4 2022 | $55,320 | +53.7% | 34,575 | +36.0% | 0.00% | – |
Q3 2022 | $36,000 | -47.1% | 25,430 | -32.2% | 0.00% | – |
Q2 2022 | $68,000 | -80.8% | 37,501 | -18.5% | 0.00% | -100.0% |
Q1 2021 | $355,000 | -79.7% | 45,988 | -82.8% | 0.00% | -75.0% |
Q4 2020 | $1,749,000 | +18.6% | 266,986 | +20.4% | 0.01% | +33.3% |
Q3 2020 | $1,475,000 | -8.9% | 221,812 | +14.1% | 0.01% | -25.0% |
Q2 2020 | $1,619,000 | -22.5% | 194,412 | -28.6% | 0.01% | -42.9% |
Q1 2020 | $2,089,000 | -21.6% | 272,410 | -15.0% | 0.01% | +55.6% |
Q4 2019 | $2,665,000 | +3406.6% | 320,655 | +2999.3% | 0.01% | – |
Q3 2019 | $76,000 | -91.4% | 10,346 | -87.4% | 0.00% | -100.0% |
Q1 2019 | $879,000 | -57.6% | 81,798 | -40.4% | 0.00% | -66.7% |
Q4 2018 | $2,073,000 | -36.4% | 137,261 | -22.1% | 0.01% | -25.0% |
Q3 2018 | $3,259,000 | -60.6% | 176,160 | -51.3% | 0.01% | -64.7% |
Q2 2018 | $8,270,000 | -28.7% | 361,750 | -11.2% | 0.03% | -35.8% |
Q1 2018 | $11,593,000 | – | 407,483 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 6,450,000 | $8,320,500 | 1.17% |
BVF INC/IL | 6,595,801 | $8,508,583 | 0.23% |
Bronte Capital Management Pty Ltd. | 925,245 | $1,193,566 | 0.12% |
Formidable Asset Management, LLC | 318,111 | $410,363 | 0.09% |
Congress Park Capital LLC | 112,450 | $145,061 | 0.08% |
Forefront Analytics, LLC | 49,421 | $63,754 | 0.04% |
Ground Swell Capital, LLC | 10,966 | $14,146 | 0.02% |
Clearline Capital LP | 196,583 | $253,592 | 0.02% |
CORNERCAP INVESTMENT COUNSEL INC | 81,352 | $104,944 | 0.02% |
ACADIAN ASSET MANAGEMENT LLC | 2,646,190 | $3,412 | 0.01% |